Related Experiment Video

Updated: Aug 19, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

[Growth hormone treatment in children with short stature due to IUGR]

Reiko Horikawa1

  • 1Division of Adolescent medicine, National Center for Child Health and Development.

Clinical Calcium
|March 19, 2005
PubMed

Insights

Most children with intrauterine growth retardation catch up in growth, but 10% remain short. Growth hormone therapy improves height and psychosocial outcomes in short children, though long-term effects require monitoring.

Area of Science:

  • Pediatric Endocrinology
  • Growth and Development
  • Reproductive Medicine

Context:

  • Intrauterine growth retardation (IUGR) affects fetal development.
  • A significant minority of IUGR children experience persistent short stature.
  • Catch-up growth is typical, but some children require intervention.

Purpose:

  • To evaluate the efficacy of growth hormone (GH) therapy in children with short stature due to IUGR.
  • To assess the long-term outcomes of GH treatment, including final height and psychosocial well-being.
  • To identify potential risks associated with high-dose GH therapy in early childhood.

Summary:

  • Growth hormone therapy is effective for improving height and psychosocial status in short children with IUGR.
  • Favorable results are observed in both linear growth and psychosocial positiveness.
  • Long-term monitoring is crucial to assess effects on puberty and metabolism.

Impact:

  • GH therapy offers a viable treatment for persistent short stature in IUGR children.
  • Understanding long-term effects is vital for optimizing treatment protocols.
  • Further research is needed on metabolic effects like glucose intolerance and pubertal development.

More Related Videos

Treatment of Ligament Constructs with Exercise-conditioned Serum: A Translational Tissue Engineering Model08:03

Treatment of Ligament Constructs with Exercise-conditioned Serum: A Translational Tissue Engineering Model

Published on: June 11, 2017

Related Concept Videos

Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...